Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 6, 2006, Pages 727-735

  Trocòniz, Iñaki F ^a   Garrido, María J ^a   Segura, Cristina ^a   Cendrós, Josep María ^b   Principe, Paola ^b   Peraire, Concepción ^b   Obach, Rosendo ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IPSEN   (France)

Author keywords

Diflomotecan; Neutropenia; NONMEM; Phase I; Population Pharmacokinetic Pharmacodynamic; Semimechanistic model

Indexed keywords

DIFLOMOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD LEVEL; BREAST CARCINOMA; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; EVALUATION; FATIGUE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PAROTID GLAND CARCINOMA; PHASE 1 CLINICAL TRIAL; POPULATION DISTRIBUTION; POPULATION MODEL; PRIORITY JOURNAL; SOFT TISSUE CANCER; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; FEMALE; FRANCE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTICENTER STUDIES; NEOPLASMS; NEUTROPENIA;

EID: 33645744463     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0112-6     Document Type: Article

References (25)

1. Bailly C (2003) Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol 45:91-108
2. Ulukan H, Swaan PW (2002) Camptothecins. A review of their chemotherapeutic potential. Drugs 62:2039-2057
3. Lavergne O, Demarquay D, Kasprzyk PG, Bigg DC (2000) Homocamptothecins: E-ring modified CPT analogues. Ann N Y Acad Sci 922: 100-111
4. Versace RW (2003) The silatecans, a novel class of lipophilic camptothecins. Expert Opin Ther Patents 13:751-760
5. Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Kasprzyk PG, Bailly Ch, Cámara J, Bigg DCH (2001) The homocampthotecin BN80915 is a highly potent orally active topoisomerase I poison. Anti-Cancer Drugs 12:9-19
6. Lansiaux A, Facompre M, Wattez N, Hildebrand MP, Bal C, Demarquay D, Lavergne O, Bigg DC, Bailly C (2001) Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 Cells. Mol Pharmacol 60:450-461
7. Huchet M, Demarquay D, Coulomb H, Kasprzyk P, Carlson M, Lauer J, Lavergne O, Bigg D (2000) The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann N Y Acad Sci 922: 303-305
8. Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJA, Devlin M, van Hooije Ch, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves Ch (2003) Phase I Pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified Camptothecin analogue in adults with solid tumors. Clin Cancer Res 9:4101-4107
9. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves Ch, Verweij J, McLeod HL (2004) Diflomotecan pharmacokinetics in relation to ABCG2421-C > A genotype. Clin Pharmacol Ther 76:38-44
10. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chaemotherapy-induced myelosupression with parameter consistency across drugs. J Clin Oncol 20:4713-4721
11. Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A (2005) Relationship of systemic exposure to unbound docetaxel and neutropaenia. Clin Pharmacol Ther 77:43-53
12. Beal SL, Sheiner LB (1992) (eds) NONMEM user's guides. NONMEM Project Group, University of California at San Francisco, San Francisco
13. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models; I: models for covariate effects. J Pharmacokinet Biopharm 20:511-528
14. Jonsson EN, Karlsson MO (1999) Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64
15. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-12
16. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171-192
17. Mould DR, Holford NHG, Schellens JHM, Beijnen JH, Hutson PR, Rosing H, ten Bokkel Huinink WW, Rowinsky EK, Schiller JH, Russo M, Ross G (2002) Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71: 334-348
18. Schellens JHM, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR (2002) Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. Invest New Drug 20:83-93
19. Xie R, Mathijssen RHJ, Sparreboom A, Verweij J, Karlsson MO (2002) Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 72:265-275
20. Mathijssen RHJ, Verweij J, de Jongue MJA, Nooter K, Stoter G, Sparreboom A (2002) Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 20:81-87
21. Solá J, Gay-Feutry C, Massiere F, Peraire C, Obach R, Principe P (2003) In vitro metabolism of diflomotecan in humans. Evaluation of the CYP inhibition potential. Drug Metab Rev 35(Supp 1):51
22. Baker SD, Verweij J, Rowisnky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A (2002) Role of body surface area in dosing investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 94:1883-1888
23. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340
24. Larsen AK, Gilbert C, Chyzak G, Plisov SY, Naguibneva I, Lavergne O, Lesueur-Ginot L, Bigg DCH (2001) Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res 61:2961-2967
25. Philippart P, Harper L, Chaboteaux C, Decaestecker Ch, Bronckart Y, Gordover L, Leseur-Ginot L, Malonne H, Lavergne O, Bigg DCH, Mendes da Costa P, Kiss R (2000) Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin Cancer Res 6:1557-1562